All the news

Advanced liver fibrosis in people with non-alcoholic fatty liver disease was associated with an increased risk of liver-related complications, a prospective study in the United States has found. Fat accumulation in the liver, ...

People with HIV were more likely to develop fatty liver disease if they took antiretroviral treatment that contains an integrase inhibitor or tenofovir alafenamide (TAF), a German research group has found. Non-alcoholic ...

Resmetirom, a thyroid hormone receptor agonist, appeared to reduce liver fat and fibrosis, as determined by biomarkers and non-invasive imaging, in people with non-alcoholic steatohepatitis (NASH), according to a presentation at the 2021 International ...

Food insecurity – limited or unreliable food supplies due to poverty – was associated with an increased risk of death in US adults with non-alcoholic fatty liver disease (NAFLD) or advanced fibrosis ...

Having HIV almost doubles the risk of liver fibrosis, according to European research published in the online edition of the Journal of Infectious Diseases. Investigators in Denmark and the Netherlands ...

Semaglutide, a medication approved to treat type 2 diabetes, increased the likelihood of improvement in non-alcoholic steatohepatitis (NASH) without worsening liver fibrosis, researchers reported at the AASLD virtual Liver Meeting. What's more, ...

Twenty-four weeks of treatment with lanifibranor, a drug designed to treat NASH, improved liver fibrosis in 42% of people treated in a phase 2b clinical trial, Professor Sven Francque of Antwerp ...

Efruxifermin reduced liver fat and improved liver inflammation and fibrosis in the majority of people with NASH who received it in a phase 2a trial but nausea and vomiting led 10% of ...